Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers
Status:
Completed
Trial end date:
2020-12-03
Target enrollment:
Participant gender:
Summary
This is a Phase 1, first in human (FIH), randomised, active-controlled, double-blind study
designed to assess the safety and tolerability and explore preliminary efficacy of the EG-HZ
vaccine. Oversight will be provided by a Safety Review Committee (SRC).